<DOC>
	<DOCNO>NCT01545791</DOCNO>
	<brief_summary>This study conduct Europe . The aim study observe safety insulin detemir ( Levemir® ) patient type 1 type 2 diabetes patient .</brief_summary>
	<brief_title>Observational Study Evaluate Safety Levemir® Patients With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Any patient type 1 type 2 diabetes mellitus , include newly diagnose patient never receive insulin insulin analogue Patients physician consider might noncompliant reason ; example , uncooperative attitude , inability return final visit similar Patients previously enrol study Patients hypersensitivity insulin detemir</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>